Explore NVO stock price, technical analysis, earnings, and forecast. Is NVO stock a buy? Get balanced insights on Novo Nordisk’s valuation and outlook as of February 2026.
Introduction
Novo Nordisk makes drugs for diabetes and obesity. Its top products are Ozempic and Wegovy. Investors watch NVO stock now due to GLP-1 demand and competition. Broader markets face rate cuts and health sector shifts.
NVO stock draws focus amid obesity drug boom. Economic slowdowns hit pharma less. This analysis covers NVO stock price trends and risks.
Latest Stock Price & Trend
NVO stock closed at $38.08 on February 25, 2026. It fell from $38.59 prior close, down about 1.3% in the day.
Over five days, NVO stock shows pullback pressure. One-month trend dropped 27% from December highs around $62.
Three-month gain sits at 11%, but six-month loss hits 7%. Year-to-date, it’s up 22% early but reversed sharply.
52-week range spans $37.68 low to $93.78 high. Overall trend turned bearish from 2025 peaks. This signals caution for investors as momentum fades.
Technical Analysis
Support levels sit near $37.68, the 52-week low. Resistance looms at $39-40, past recent highs. These levels matter as they show buy/sell zones.
RSI reads 16.9-39, oversold to neutral. Oversold means potential rebound if buyers step in.
MACD stays bearish, line below signal. This flags short-term down momentum.
50-day moving average tops 200-day now, no golden cross. Moving averages track trends; crossover signals shifts.
Volume spiked to 34 million shares lately, above average. High volume confirms trend strength.
Analyst Ratings & Price Targets
Analysts rate NVO stock Hold. 34 firms give average target $53-54, up 40% from $38. High $70, low $46.
Recent views stay overweight. No big upgrades noted. Wall Street sees fair value amid growth slowdown.
Hold means steady, not aggressive buy. Investors use this for conviction gauge.
Insider Activity
No recent insider buys or sells reported. Zero trades in last period.
Company holds treasury shares at 0.4%. Management shows neutral stance.
Flat activity implies no strong confidence signal or alarm. Watch for changes.
Valuation Analysis
Trailing P/E ratio at 12.34, below historical 27 average. Forward P/E similar.
Price-to-sales low versus peers. Revenue grew YoY, but Q3 net profit dipped to 26.7%. EPS up 4% to DKK 16.99.
Free cash flow strong at DKK 63.9B nine months. Debt managed, cash solid.
Versus LLY (P/E 45) or AZN (31), NVO looks undervalued. Low ratios suggest bargain if growth holds.
Recent Earnings & Catalysts
Q3 2025 revenue beat views slightly. Operating profit up 21% constant rates. EPS met at DKK 16.99.
Guidance narrowed for year. Q4 due February 4, 2026, eyes $11.96B revenue, $0.89 EPS.
Catalysts include Wegovy pill approval, amycretin trials. Earnings dipped stock on margin worry.
Bullish Case
GLP-1 demand drives revenue. Obesity market expands.
Wegovy expansions boost sales. Pipeline like CagriSema adds edge.
Operational scale aids margins long-term.
Bearish Case
Competition from LLY pressures pricing. Growth slows post-boom.
Margin squeeze hit Q3 at 26.7%. Short interest up 9% to 0.71%.
Regulatory risks on GLP-1 drugs loom.
Market Sentiment
Short interest at 0.71%, days to cover 1.8-2.0. Low but rising.
Institutions own heavily, 1502 long funds, down slightly. Retail follows momentum down.
Sentiment neutral to cautious amid pullback.
Short-Term Outlook
Oversold RSI hints rebound chance. Volume high supports moves. Bearish MACD caps gains. Expect volatility next weeks pre-earnings.
Medium to Long-Term Outlook
Strong diabetes/obesity model. Industry grows 10%+. Competitive moat via brands.
Financials healthy, but watch competition. Long-term holders should hold; accumulate on dips if valuation stays low.
FAQ
Is NVO stock a buy right now? Hold per analysts; undervalued but risks high.
What is the price target for NVO stock? Average $54, range $46-70.
What are major risks for NVO stock? Competition, margins, slowing growth.
NVO earnings next? Q4 February 4, 2026.
NVO forecast long-term? Positive if pipeline delivers.
Suggestions
- Compare with Opendoor stock analysis
- See our Eli Lilly earnings breakdown
- Read pharma sector valuation guide
Final Balanced Conclusion
Hold NVO stock. Valuation attractive, but bearish trends and risks warrant caution. Growth intact long-term.
Disclaimer: This article is for informational purposes only and not financial advice.